Literature DB >> 16369043

Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen.

Kristina K Peachman1, Mangala Rao, Carl R Alving, Robert Burge, Stephen H Leppla, Venigalla B Rao, Gary R Matyas.   

Abstract

Transcutaneous immunization of mice with recombinant protective antigen (rPA) of Bacillus anthracis resulted in significantly higher lethal toxin-neutralizing antibody titers than did intramuscular injection of alum-adsorbed rPA. Immunized mice were partially protected against intranasal challenge with 235,000 (10 50% lethal doses) Ames strain B. anthracis spores. A highly significant correlation was observed between toxin-neutralizing antibody titer and survival after challenge. Future experiments with rabbits and nonhuman primates should confirm the significance of protection by this vaccine strategy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16369043      PMCID： PMC1346607          DOI： 10.1128/IAI.74.1.794-797.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  13 in total

1.  Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax.

Authors:  Melissa Drysdale; Sara Heninger; Julie Hutt; Yahua Chen; C Rick Lyons; Theresa M Koehler
Journal:  EMBO J       Date:  2004-12-16       Impact factor: 11.598

2.  Differences in susceptibility of inbred mice to Bacillus anthracis.

Authors:  S L Welkos; T J Keener; P H Gibbs
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

3.  Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis.

Authors:  D M Ramirez; S H Leppla; R Schneerson; J Shiloach
Journal:  J Ind Microbiol Biotechnol       Date:  2002-04       Impact factor: 3.346

Review 4.  Anthrax vaccines.

Authors:  A M Friedlander; S L Welkos; B E Ivins
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

5.  Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals.

Authors:  L C Iacono-Connors; S L Welkos; B E Ivins; J M Dalrymple
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

6.  Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.

Authors:  S F Little; B E Ivins; P F Fellows; M L M Pitt; S L W Norris; G P Andrews
Journal:  Vaccine       Date:  2004-01-02       Impact factor: 3.641

7.  Validation of the anthrax lethal toxin neutralization assay.

Authors:  Donna Hering; William Thompson; John Hewetson; Stephen Little; Sarah Norris; Judith Pace-Templeton
Journal:  Biologicals       Date:  2004-03       Impact factor: 1.856

8.  Needle-free skin patch vaccination method for anthrax.

Authors:  Gary R Matyas; Arthur M Friedlander; Gregory M Glenn; Stephen Little; Jianmei Yu; Carl R Alving
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

9.  Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages.

Authors:  Nehal Mohamed; Juan Li; Claudia S Ferreira; Stephen F Little; Arthur M Friedlander; George L Spitalny; Leslie S Casey
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

10.  Induction of protective immunity against lethal anthrax challenge with a patch.

Authors:  Richard T Kenney; Jianmei Yu; Mimi Guebre-Xabier; Sarah A Frech; Adam Lambert; Barbara A Heller; Larry R Ellingsworth; James E Eyles; E Diane Williamson; Gregory M Glenn
Journal:  J Infect Dis       Date:  2004-07-13       Impact factor: 5.226
View more
  27 in total

1.  Comparison of three anthrax toxin neutralization assays.

Authors:  Miriam M Ngundi; Bruce D Meade; Tsai-Lien Lin; Wei-Jen Tang; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

2.  Multicomponent anthrax toxin display and delivery using bacteriophage T4.

Authors:  Sathish B Shivachandra; Qin Li; Kristina K Peachman; Gary R Matyas; Stephen H Leppla; Carl R Alving; Mangala Rao; Venigalla B Rao
Journal:  Vaccine       Date:  2006-10-17       Impact factor: 3.641

3.  Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production.

Authors:  Afton L Thompson; Brandi T Johnson; Gregory D Sempowski; Michael D Gunn; Baidong Hou; Anthony L DeFranco; Herman F Staats
Journal:  J Immunol       Date:  2012-02-15       Impact factor: 5.422

4.  Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.

Authors:  Chandrabali Ghose; Anuj Kalsy; Alaullah Sheikh; Julianne Rollenhagen; Manohar John; John Young; Sean M Rollins; Firdausi Qadri; Stephen B Calderwood; Ciaran P Kelly; Edward T Ryan
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

5.  Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.

Authors:  Qin Li; Kristina K Peachman; Laurie Sower; Stephen H Leppla; Sathish B Shivachandra; Gary R Matyas; Johnny W Peterson; Carl R Alving; Mangala Rao; Venigalla B Rao
Journal:  Open Vaccine J       Date:  2009

6.  Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice.

Authors:  Julianne E Rollenhagen; Anuj Kalsy; Francisca Cerda; Manohar John; Jason B Harris; Regina C Larocque; Firdausi Qadri; Stephen B Calderwood; Ronald K Taylor; Edward T Ryan
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

7.  Highly effective generic adjuvant systems for orphan or poverty-related vaccines.

Authors:  Mangala Rao; Kristina K Peachman; Qin Li; Gary R Matyas; Sathish B Shivachandra; Richard Borschel; Venee I Morthole; Carmen Fernandez-Prada; Carl R Alving; Venigalla B Rao
Journal:  Vaccine       Date:  2010-11-27       Impact factor: 3.641

8.  Mice Housed at Elevated Vivarium Temperatures Display Enhanced T-cell Response and Survival to Francisella tularensis.

Authors:  Robert L Rubin
Journal:  Comp Med       Date:  2017-12-01       Impact factor: 0.982

9.  Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination.

Authors:  Sha Cao; Aizhen Guo; Ziduo Liu; Yadi Tan; Gaobing Wu; Chengcai Zhang; Yaxing Zhao; Huanchun Chen
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

10.  Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species.

Authors:  Kristian S Omland; April Brys; David Lansky; Kristin Clement; Freyja Lynn
Journal:  Clin Vaccine Immunol       Date:  2008-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.